Table 3 Proportion of patients using oral antidiabetic drugs (OHA) prior to insulin initiation and at end of study
Body mass index (BMI) at baseline | ||||
|---|---|---|---|---|
BMI <25 | 25 ≤ BMI < 30 | 30 ≤ BMI < 35 | BMI ≥ 35 | |
Biguanide | ||||
Baseline | 71.2% | 81.8% | 85.8% | 87.0% |
Final Visit | 65.1% | 80.5% | 85.2% | 86.5% |
Change | -6.1% | -1.3% | -0.6% | -0.5% |
Glinides | ||||
Baseline | 19.5% | 16.3% | 14.7% | 13.5% |
Final Visit | 24.7% | 18.8% | 17.1% | 16.1% |
Change | +5.2% | +2.5% | +2.4% | +2.6% |
Alpha Glucosidase Inhibitor | ||||
Baseline | 19.9% | 12.2% | 8.6% | 7.8% |
Final Visit | 21.4% | 12.5% | 7.8% | 6.6% |
Change | +1.5% | +0.3% | -0.8% | -1.2% |
Sulphonylureas | ||||
Baseline | 57.9% | 58.5% | 61.7% | 60.3% |
Final Visit | 41.4% | 43.3% | 46.4% | 45.3% |
Change | -16.5% | -15.2% | -15.3% | -15.0% |
Thiazolidinediones | ||||
Baseline | 10.9% | 11.3% | 12.8% | 15.2% |
Final Visit | 7.3% | 7.9% | 7.7% | 8.2% |
Change | -3.6% | -3.4% | -5.1% | -7.0% |
Dipeptidyl peptidase IV Inhibitors | ||||
Baseline | 3.8% | 5.9% | 7.9% | 9.6% |
Final Visit | 2.8% | 5.2% | 6.5% | 7.2% |
Change | -1.0% | -0.7% | -1.4% | -2.4% |